Although HER2-mutant BTCs may not be as responsive to HER2 monoclonal antibodies as HER2-amplified or -overexpressed cancer types, irreversible HER2 inhibitors such as neratinib seem to be promising treatment options. This evidence concerns the gene ERBB2 and cancer.